套细胞淋巴瘤死亡限制序贯治疗,尤其在一线复发后:澳大利亚与英国系列患者的诊疗模式与结局
该多中心回顾性队列分析纳入澳大利亚和英国中心10年间治疗的389例套细胞淋巴瘤患者,评估淋巴瘤相关死亡导致序贯治疗受限的问题。结果显示接受第一、二、三线治疗后分别有7%、23%、26%的患者死于未控制的套细胞淋巴瘤,诊断时年龄较大和诱导治疗后早期复发者二线治疗后死亡风险尤其高。
要点
- 接受第一、二、三线治疗后分别有7%、23%、26%的患者死于未控制的套细胞淋巴瘤。
- 诊断时年龄较大和诱导治疗后早期复发者二线治疗后死亡风险尤其高。
- 淋巴瘤相关死亡限制序贯治疗,为在高风险人群中较早线试用新疗法提供支持。
核心结论
- 淋巴瘤相关死亡限制序贯治疗,支持在高风险患者群体中较早线试用新疗法。
研究设计与样本
- 多中心回顾性队列分析,纳入澳大利亚和英国中心10年间治疗的389例套细胞淋巴瘤患者。
主要发现
- 接受第一、二、三线治疗后分别有7%、23%、26%的患者死于未控制的套细胞淋巴瘤。
- 诊断时年龄较大和诱导治疗后早期复发者二线治疗后死亡风险尤其高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about optimal therapy sequencing. Novel agents, such as chimeric antigen receptor T-cell therapies and bispecific antibodies, show promise in relapsed MCL, but are often reserved for later treatment lines, which may underserve patients with aggressive disease phenotypes who die early in the treatment journey. To assess the problem of patient attrition from lymphoma-related death limiting sequential treatment, we performed a multicentre retrospective cohort analysis of 389 patients treated at Australian and UK centres over a 10-year period. Deaths from MCL increased after each treatment line, with 7%, 23% and 26% of patients dying from uncontrolled MCL after first, second and third lines respectively. Patients with older age at diagnosis and early relapse after induction therapy were at particular risk of death after second-line treatment. This limitation of sequential treatment by lymphoma-related death provides support for the trial of novel therapies in earlier treatment lines, particularly in high-risk patient populations.
引用
- Minson A, Hamad N, Di Ciaccio P, et al. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. Br J Haematol. 2023. PMID: 37904342. doi:10.1111/bjh.19179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。